William Garrett Nichols sold $3,936 of CADL
Chief Medical Officer at Candel Therapeutics, Inc.. 781 shares at an average of $5.04, traded Jun 30, 2025, filed Jul 2, 2025.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +26.1%, 3m +11.0%, 6m +13.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-093035, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2025 | MOption exercise Common Stock10b5-1 | +781 | $1.29 | $1,007 | 53,274 | Jul 2, 2025 |
| Jun 30, 2025 | SOpen-market sale Common Stock10b5-1 | -781 | $5.04 | $3,936 | 52,493 | Jul 2, 2025 |
| Jun 30, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -781 | $0.00 | $0 | 30,314 | Jul 2, 2025 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $3.2M 280,245 shares | -71% | |
| 4Weak | Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $84k 7,000 shares | -8% | |
| 21Weak | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $236k 23,447 shares | -23% | |
| 11Weak | Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $70k 7,000 shares | -8% | |
| 54Moderate | CADLbuy Candel Therapeutics, Inc. | Paul B Manning director | $3.0M 550,458 shares | +25% | |
| 0Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $6,540 937 shares | -2% | |
| 14Weak | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $282k 32,146 shares | -25% | |
| 38Weak | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $230k 26,172 shares | -10% | |
| 21Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $397k 45,316 shares | -46% | |
| 21Weak | Candel Therapeutics, Inc. | Charles Schoch See Remarks | $44k 5,000 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.